ETC
SUPN icon

Exchange Traded Concepts’s Supernus Pharmaceuticals SUPN Stock Holding History

Exchange Traded Concepts’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
40,971
+603
+1% +$29K 0.01% 734
2026
Q1 		$2.09M Buy
40,368
+23,316
+137% +$1.19M 0.01% 600
2025
Q4 		$847K Sell
17,052
-498
-3% -$24.2K 0.01% 878
2025
Q3 		$839K Sell
17,550
-7,815
-31% -$315K 0.01% 841
2025
Q2 		$800K Buy
25,365
+484
+2% +$15.5K 0.01% 767
2025
Q1 		$815K Buy
24,881
+2,762
+12% +$97.9K 0.01% 642
2024
Q4 		$800K Buy
22,119
+560
+3% +$19.7K 0.02% 658
2024
Q3 		$672K Buy
+21,559
New +$673K 0.02% 703
2024
Q1 		– Sell
-42,189
Closed -$1.22M – 1417
2023
Q4 		$1.22M Buy
42,189
+335
+0.8% +$8.88K 0.03% 360
2023
Q3 		$1.15M Buy
41,854
+26,390
+171% +$803K 0.03% 353
2023
Q2 		$465K Sell
15,464
-510
-3% -$17.8K 0.01% 627
2023
Q1 		$579K Sell
15,974
-3,964
-20% -$152K 0.02% 513
2022
Q4 		$711K Buy
19,938
+540
+3% +$18.8K 0.02% 378
2022
Q3 		$657K Sell
19,398
-74
-0.4% -$2.41K 0.02% 332
2022
Q2 		$563K Buy
19,472
+444
+2% +$12.7K 0.02% 462
2022
Q1 		$615K Sell
19,028
-27,607
-59% -$846K 0.01% 517
2021
Q4 		$1.36M Buy
46,635
+813
+2% +$24.7K 0.03% 296
2021
Q3 		$1.22M Buy
45,822
+9,717
+27% +$261K 0.03% 288
2021
Q2 		$1.11M Buy
36,105
+3,433
+11% +$105K 0.04% 301
2021
Q1 		$855K Buy
32,672
+4,362
+15% +$122K 0.03% 316
2020
Q4 		$712K Buy
28,310
+2,760
+11% +$59.4K 0.03% 277
2020
Q3 		$532K Buy
25,550
+4,414
+21% +$100K 0.03% 289
2020
Q2 		$502K Buy
+21,136
New +$467K 0.08% 210

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Exchange Traded Concepts's SUPN Position: Q2 2026 in Review

Exchange Traded Concepts increased its Supernus Pharmaceuticals (SUPN) stake by 1.5% in Q2 2026, buying an estimated $29K and bringing the position to 40,971 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #734.

Exchange Traded Concepts first reported a position in SUPN in Q2 2020 and has held it in 23 quarters since. The position peaked at $2.09M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Exchange Traded Concepts held 40,971 shares of Supernus Pharmaceuticals worth $1.91M as of Q2 2026.
  • Exchange Traded Concepts bought 603 Supernus Pharmaceuticals shares in Q2 2026, an estimated $29K.
  • Supernus Pharmaceuticals made up 0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #734 holding.
  • Exchange Traded Concepts first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Exchange Traded Concepts's Supernus Pharmaceuticals position peaked at $2.09M in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.